Atopic Dermatitis

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

Dr. Karan Lal offers insights into diagnosing various forms of rosacea as well as common treatment methods.

This is the first topical treatment approved by the FDA for facial angiofibroma associated with tuberous sclerosis complex in adults and children 6 years and older.

Previous research suggested that inpatient dermatology services not only improved diagnostic accuracy but reduced readmissions.

A consensus was reached on nearly all proposals in the eDelphi study, which members said could be used to establish a clear dosing regimen for methotrexate.

Data from the ADhere studies found that lebrikizumab was well tolerated in patients with atopic dermatitis.

New phase 2 data from the KARE study presented at AAD found that the therapy improved itch severity and sleep in patients with atopic dermatitis and pruritis.

Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.

Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.

Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.

Dupilumab is the first biologic to show positive phase 3 results in patients with prurigo nodularis.

New data suggest that treatment with dupilumab does not increase the risk of COVID-19 infection in patients with atopic diseases.

The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

Dr. Elena B. Hawryluk details her pre-AAD session, the variety of conversations being held at the meeting, and how these conversations can inform dermatological research outside of the pediatric field.

IL-17 inhibitors were also associated with higher persistence than IL-12 and IL-23 inhibitors for psoriatic arthritis, though no difference was observed for psoriasis.

Closing out their discussion on the management of atopic dermatitis, expert panelists share clinical pearls and key takeaways from their discussion.

Shared insight on the best ways to educate patients on their atopic dermatitis and explain the nuances of available therapies.

A broad look at the ongoing challenges and unmet needs in the field of atopic dermatitis management.

Marc Serota, MD, elucidates the heterogeneity of atopic dermatitis and explains how this can contribute to challenges in treating patients.

Expert panelists share excitement for novel therapies in the pipeline for the management of atopic dermatitis.

Taking into account all available topical and systemic therapies, Marc Serota, MD, provides his optimal sequencing strategy for patients with atopic dermatitis.

Drs. Lio, Feldman and Jain reflect on the adverse event profile of JAK inhibitor therapy in atopic dermatitis and consider when these agents are appropriate for use.

An overview of the three JAK inhibitor therapies available for the management of atopic dermatitis.

Potent and moderate topical corticosteroids were likely to be effective than milder options for patients with moderate or severe eczema.